NCT06079333View on ClinicalTrials.gov

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
Anaplastic Thyroid Cancer
Interventions
DRUG

dabrafenib/trametinib

braf/mek-inhibition

Trial Locations (1)

2300RC

RECRUITING

Ellen Kapiteijn, Leiden

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Leiden University Medical Center

OTHER